Could an allergy drug boost lung cancer treatment? new trial investigates.
NCT ID NCT07358689
First seen Feb 01, 2026 · Last updated Jun 03, 2026 · Updated 27 times
Summary
This phase 2 trial tests whether adding an allergy medicine (diphenhydramine) to standard immunotherapy (toripalimab) and chemotherapy helps shrink lung tumors before surgery and prevents cancer from coming back after surgery. About 120 adults with stage IIA-IIIB non-small cell lung cancer will be randomly assigned to receive either the three-drug combo or just toripalimab plus chemo. The main goal is to see if the allergy drug leads to a complete disappearance of cancer cells in the removed tumor tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.